There is no fee for this activity. To receive credit for this CME/CPE/CE activity, complete the pre-activity assessment, view the video(s) and complete the post-activity assessment and evaluation/application for credit. Upon completion of course requirements, you will be able to print your certificate.
CE Credit Available Until: June 4, 2019
Hematologists-oncologists, oncologists, physician assistants, pharmacists, nurse practitioners, nurses, and oncology social workers at the intermediate and advanced levels involved in the care of patients with hematologic malignancies.
At the conclusion of this program, participants will be able to:
- Describe the latest developments in immunotherapy for patients with relapsed/refractory blood cancer
- Explain the emerging role of chimeric antigen receptor (CAR) T-cell treatment options
- Discuss treatment plans for patient care
- Explain potential short- and long-term side effects and management
- Be more prepared to identify patients who could potentially be treated with CAR therapy
- Engage patients and caregivers in discussions on CAR T-cell therapies including benefits, risks, and barriers to entry
Jointly provided by The Leukemia & Lymphoma Society and Medical Learning Institute, Inc.
Sponsors and Supporters
This activity is supported by educational grants from Juno, a Celgene Company and Kite, a Gilead Company.